GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Merck & Co Inc (BUE:MRK) » Definitions » Beneish M-Score

Merck (BUE:MRK) Beneish M-Score

: -2.99 (As of Today)
View and export this data going back to . Start your Free Trial

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.99 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Merck's Beneish M-Score or its related term are showing as below:

BUE:MRK' s Beneish M-Score Range Over the Past 10 Years
Min: -2.99   Med: -2.73   Max: -2.24
Current: -2.99

During the past 13 years, the highest Beneish M-Score of Merck was -2.24. The lowest was -2.99. And the median was -2.73.


Merck Beneish M-Score Historical Data

The historical data trend for Merck's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Merck Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.71 -2.66 -2.24 -2.58 -2.99

Merck Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Beneish M-Score Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.58 -2.54 -2.94 -2.99 -2.99

Competitive Comparison

For the Drug Manufacturers - General subindustry, Merck's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Merck Beneish M-Score Distribution

For the Drug Manufacturers industry and Healthcare sector, Merck's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Merck's Beneish M-Score falls into.



Merck Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Merck for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.0691+0.528 * 0.9694+0.404 * 1.0123+0.892 * 2.2057+0.115 * 1.0628
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.0165+4.679 * -0.091482-0.327 * 1.1468
=-1.82

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Total Receivables was ARS3,735,989 Mil.
Revenue was 5281430.005 + 5585902.054 + 3608399.971 + 2861906.917 = ARS17,337,639 Mil.
Gross Profit was 3869198.003 + 4093715.213 + 2642639.979 + 2086325.599 = ARS12,691,879 Mil.
Total Current Assets was ARS11,612,648 Mil.
Total Assets was ARS38,509,675 Mil.
Property, Plant and Equipment(Net PPE) was ARS8,321,411 Mil.
Depreciation, Depletion and Amortization(DDA) was ARS1,115,345 Mil.
Selling, General, & Admin. Expense(SGA) was ARS3,031,975 Mil.
Total Current Liabilities was ARS9,275,534 Mil.
Long-Term Debt & Capital Lease Obligation was ARS12,159,563 Mil.
Net Income was -442586 + 1660512.796 + -1433999.989 + 557288.563 = ARS341,215 Mil.
Non Operating Income was -33573 + -2799.6 + -37200 + -5136.3 = ARS-78,709 Mil.
Cash Flow from Operations was 88806 + 2700564.224 + 888959.993 + 264519.456 = ARS3,942,850 Mil.
Total Receivables was ARS1,584,292 Mil.
Revenue was 2318599.436 + 2078553.019 + 1755975.714 + 1707323.041 = ARS7,860,451 Mil.
Gross Profit was 1667949.804 + 1531923.727 + 1248664.427 + 1129661.387 = ARS5,578,199 Mil.
Total Current Assets was ARS5,988,793 Mil.
Total Assets was ARS18,300,673 Mil.
Property, Plant and Equipment(Net PPE) was ARS3,591,398 Mil.
Depreciation, Depletion and Amortization(DDA) was ARS515,923 Mil.
Selling, General, & Admin. Expense(SGA) was ARS1,352,324 Mil.
Total Current Liabilities was ARS4,063,668 Mil.
Long-Term Debt & Capital Lease Obligation was ARS4,819,099 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(3735989.003 / 17337638.947) / (1584292.456 / 7860451.21)
=0.215484 / 0.201552
=1.0691

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(5578199.345 / 7860451.21) / (12691878.794 / 17337638.947)
=0.709654 / 0.732042
=0.9694

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (11612648.01 + 8321411.007) / 38509675.035) / (1 - (5988793.134 + 3591398.201) / 18300673.494)
=0.482362 / 0.476512
=1.0123

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=17337638.947 / 7860451.21
=2.2057

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(515923.087 / (515923.087 + 3591398.201)) / (1115345.363 / (1115345.363 + 8321411.007))
=0.125611 / 0.118192
=1.0628

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(3031974.531 / 17337638.947) / (1352323.78 / 7860451.21)
=0.174878 / 0.172041
=1.0165

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((12159563.011 + 9275534.008) / 38509675.035) / ((4819099.117 + 4063668.238) / 18300673.494)
=0.556616 / 0.485379
=1.1468

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(341215.37 - -78708.9 - 3942849.673) / 38509675.035
=-0.091482

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Merck has a M-score of -1.82 suggests that the company is unlikely to be a manipulator.


Merck (BUE:MRK) Business Description

Address
126 East Lincoln Avenue, Rahway, NJ, USA, 07065
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.